Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "FY26-results"

35 News Found

Dr Lal PathLabs posts strong Q4 FY26 results with 16.6% revenue growth & PAT at Rs. 132 Cr
News | May 02, 2026

Dr Lal PathLabs posts strong Q4 FY26 results with 16.6% revenue growth & PAT at Rs. 132 Cr

The company posted revenue of Rs. 703 crore in Q4 FY26


IOL Chemicals posts robust Q3 & 9M FY26 results, PBT up 39% YoY
News | February 13, 2026

IOL Chemicals posts robust Q3 & 9M FY26 results, PBT up 39% YoY

Chemicals delivered improved efficiency and optimal capacity utilization, with EBIT rising 37% YoY


Gland Pharma reports robust Q3 FY26 results: revenue up 22%, adj. PAT soars 37%
News | January 30, 2026

Gland Pharma reports robust Q3 FY26 results: revenue up 22%, adj. PAT soars 37%

The base Gland business posted ?11,790 million in revenue, up 16% YoY


Amanta Healthcare reports 42% YoY growth in FY26 profit
News | May 20, 2026

Amanta Healthcare reports 42% YoY growth in FY26 profit

The company’s revenue stood at Rs. 287.68 crore, reflecting a 4.7 percent increase over Rs. 274.71 crore reported in FY25


Zydus Wellness FY26 revenue climbs to Rs. 39.4 billion
Healthcare | May 19, 2026

Zydus Wellness FY26 revenue climbs to Rs. 39.4 billion

Growth driven by strong performance across Sugar Free, RiteBite Max Protein, Everyuth, Glucon-D and Nutralite portfolios


KIMS Hospitals posts strong revenue growth but profits slip sharply in FY26
News | May 19, 2026

KIMS Hospitals posts strong revenue growth but profits slip sharply in FY26

Profit after tax took a sharp hit, falling to Rs. 33 Cr in Q4 FY26, down from Rs. 106 Cr in Q4 FY25 and Rs. 52 Cr in Q3 FY26


Alivus Life Sciences posts steady FY26 growth as margins surge past guidance
News | May 19, 2026

Alivus Life Sciences posts steady FY26 growth as margins surge past guidance

The company reported free cash flow of Rs. 2,590 Mn for FY26


Akums Q4 revenue climbs to Rs. 1,158 crore; PAT surges 135%
News | May 18, 2026

Akums Q4 revenue climbs to Rs. 1,158 crore; PAT surges 135%

FY26 revenue rises to Rs. 4,359 crore as India’s leading CDMO strengthens global footprint with EU GMP certifications, UK MHRA approval and Europe supplies